Abstract:345 Purpose: CTB006 is a humanized chimeric recombinant anti-human death receptor 5(DR5) agonistic antibody and can specifically bind to DR5. The purpose of this study was to validate the DR 5 expression in human. And investigates the potential of the 89Zr-CTB006 PET/CT to reveal tumor lesions and detect the DR5 expression to screen the DR5 over-expression patients with gastrointestinal cancers.\nPatients and Methods: Patients with gastrointestinal cancer that would undergo surgical operation were enrolled. All patients would undergo 18F-FDG PET/CT and 89Zr-CTB006 PET/CT. 89Zr-CTB006 PET/CT of the first six patients was undertaken 2 hours, 24 hours, 48 hours, 72 hours, 120 hours after 52.77±11MBq 89Zr-CTB006 injection. The other patients underwent 89Zr-CTB006 PET/CT 2 hours, 48 hours, 72 hours after the 89Zr-CTB006 injection. Then the tumor tissues were obtained through surgical operation and the DR5 expression levels were detected by RNAscope.\n Results: Twenty-one patients were enrolled including nine gastric cancers and twelve colorectal cancers. Three patients with colorectal cancers had received chemotherapy or radiotherapy. One patient with gastric cancer withdrew for individual reasons. The biodistribution of 89Zr-CTB006 was evaluated. Except the expected high accumulation in blood, liver and spleen, there was an astonishing finding that the adrenal glands maintained stable high uptake over the whole examination in all patients. The 89Zr-CTB006 was generally high uptake in primary tumor lesions and the metastatic lesions which was more heterogeneous than 18F-FDG and the uptake of 89Zr-CTB006 correlates with that of 18F-FDG significantly(48 h R 0.785, P\u003c0.001;72 hours R 0.791, P\u003c0.001). Both SUVmax of 18F-FDG (SUVmax: 15.26±5.78 vs 6.80±3.35, P 0.04) and 89Zr-CTB006 on 48 hours (SUVmax: 8.94±3.23 vs 4.83±0.51, P 0.005) in previously treated patients were significantly lower than untreated patients with colorectal cancers. The tumor tissue of 9 patients were obtained and the RNAscope results showed that two patients (22.2%) were 2-4 and seven patients (77.8%) were 0-1. The 89Zr-CTB006 uptake in patients with RNAscope results of 2-4 were significantly higher than patients with 0-1 both on 48 hours (SUVmax: 12.35±2.05 vs 4.75±2.21, P 0.005) and 72 hours (SUVmax: 15.48±2.15 vs 5.87±3.18, P 0.005). The tumors with higher uptake than adrenal glands were more likely to be DR5 overexpressed.\nConclusion:89Zr-CTB006 PET/CT can reveal the primary and metastatic tumor lesions with heterogenous uptake and this is the first time to find high uptake in adrenal glands. Higher 89Zr-CTB006 uptake of tumors than adrenal glands is predictive of DR5 over-expression suggesting that the uptake of adrenal glands might be the cutoff value to distinguish DR5 over-expression. Only 22.2% of the patients were DR5 overexpressed, which is much lower than expected. The DR5 expression can be downregulated by chemotherapy and radiotherapy. The study developed a noninvasive approach 89Zr-CTB006 PET/CT to detect the DR5 overexpressed tumors based on the molecular imaging.\nKey words: Death receptor 5; 89Zr-CTB006 PET/CT; Gastrointestinal cancer; molecular imaging. Foundation Support: National Natural Science Foundation of China (81671733, 81871386), Beijing Natural Science Foundation(7171002).\nEthical approval: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent was obtained from all patients. The clinical study was approved by the Ethics Committee of the Beijing Cancer Hospital (Ethics Approval License: 2018YJZ64)

Validation, Detection & Molecular Imaging Of Death Receptor 5 In Gastrointestinal Cancer Patients

First-in-human DR5 PET reveals insufficient DR5 expression in patients with gastrointestinal cancer

A Novel Fully Human Agonistic Single Chain Fragment Variable Antibody Targeting Death Receptor 5 with Potent Antitumor Activity in Vitro and in Vivo

Apoptosis-inducing effect of the DR5 monoclonal antibody, D-6, alone or in combination with cisplatin, on A2780 ovarian cancer cells.

Analysis of aDR5scFv with Specific Identification and Function.

Targeting Death Receptor 5 (DR5) for the imaging and treatment of primary bone and soft tissue tumors: an update of the literature

Death Receptor 5 Promotes Tumor Progression in Gastric Cancer.

Positron Emission Tomography Imaging of CD105 Expression with 89 Zr-Df-TRC105

Targeting Claudin 18.2 Using a Highly Specific Antibody Enables Cancer Diagnosis and Guided Surgery

The First in Human Study of <SUP>124</SUP>I-JS001 PET/CT & PET/MR Detecting PD-1 Expression In Patients with Melanoma

Combination of Novel DR5 Targeting Agonistic Scfv Antibody TR2-3 with Cisplatin Shows Enhanced Synergistic Antitumor Activity in Vitro and in Vivo

ImmunoPET and Near-Infrared Fluorescence Imaging of CD105 Expression Using a Monoclonal Antibody Dual-Labeled with (89)zr and IRDye 800CW.

Molecular SPECT/CT Profiling of Claudin18.2 Expression In Vivo: Implication for Patients with Gastric Cancer

Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors

Characterization of a Novel Anti-DR5 Monoclonal Antibody WD1 with the Potential to Induce Tumor Cell Apoptosis

Combining [11C]-Anxa5 PET Imaging with Serum Biomarkers for Improved Detection in Live Mice of Modest Cell Death in Human Solid Tumor Xenografts

Noninvasive Evaluation of Multidrug Resistance Via Imaging of ABCG2/BCRP Multidrug Transporter in Lung Cancer Xenograft Models.

Clinical Application of Radioimmunoguided Surgery in Colorectal Cancer Using125i-Labeled Carcinoembryonic Antigen-Specific Monoclonal Antibody Submucosally

Detection of Tumor Apoptotic Response in Vivo after a Single Dose of Chemotherapy with 99Tcm-Rh-annexin V

Induction of Apoptosis in U343 Cell Line by a Novel Anti-Human DR5 Monoclonal Antibody

Multimodality Imaging Of Breast Cancer Experimental Lung Metastasis With Bioluminescence And A Monoclonal Antibody Dual-Labeled With Zr-89 And Irdye 800cw